芪苈强心胶囊联合含SGLT2is新四联治疗慢性心力衰竭的效果及安全性分析

Effect and Safety Analysis of Qili Qiangxin Capsules Combined with SGLT2is New Quadruple Therapy for Chronic Heart Failure

目的:观察在慢性心力衰竭的临床治疗中,芪苈强心胶囊联合含钠-葡萄糖共转运蛋白2抑制剂(sodium glucose cotransporter 2 inhibitors,SGLT2is)新四联治疗的应用效果。方法:按照随机信封法对2021年9月—2023年6月克孜勒苏柯尔克孜自治州人民医院收治的80例慢性心力衰竭患者进行分组。对照组(40例)采用含SGLT2is新四联治疗,研究组(40例)联用芪苈强心胶囊,比较两组应用效果。结果:研究组治疗后6个月治疗总有效率、平均动脉压、左心室射血分数(left ventricular ejection fraction,LVEF)、左心室舒张早晚期充盈速度比(ventricular early to late diastolic filling velocity ratio,E/A),及治疗后1个月一氧化氮(nitric oxide,NO)水平高于对照组,且治疗后6个月左心室收缩末期容积指数(left ventricular end systolic volume index,LVESVI)、左心室舒张末期容积指数(left ventricular end diastolic volume index,LVEDVI),治疗后1个月的静息心率和氨基末端脑钠肽前体(N terminal pro B type natriuretic peptide,NT-proBNP)、内皮素-1(endothelin-1,ET-1)水平低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:芪苈强心胶囊联合含SGLT2is新四联治疗能够显著缓解慢性心力衰竭患者血管内皮功能障碍,恢复静脉系统血液循环,提高心功能,治疗安全性和实用性较高。

Objective:To observe the application effect of Qili Qiangxin Capsules combined with sodium glucose cotransporter 2 inhibitor(SGLT2is)new quadruple therapy in the clinical treatment of chronic heart failure.Method:According to the random envelope method,80 patients with chronic heart failure admitted to Kizilsu Kyrgyz Autonomous Prefecture People's Hospital from September 2021 to June 2023 were divided into two groups.The control group(40 cases)received new quadruple treatment of SGLT2is,while the study group(40 cases)received combination of Qili Qiangxin Capsules.The application effects of the two groups were compared.Result:The total effective rate and mean arterial pressure,left ventricular ejection fraction(LVEF),left ventricular early to late diastolic filling velocity ratio(E/A)at 6 months after treatment,and nitric oxide(NO)levels at 1 month after treatment in the study group were higher than those in the control group,while the left ventricular end systolic volume index(LVESVI),left ventricular end diastolic volume index(LVEDVI)at 6 months after treatment,resting heart rate,and N terminal pro B type natriuretic peptide(NT proBNP)and endothelin-1(ET-1)levels at 1 months after treatment were lower than those in the control group,the differences were statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The combination of Qili Qiangxin Capsules and SGLT2is new quadruple therapy can significantly alleviate endothelial dysfunction in patients with chronic heart failure,restore venous system blood circulation,improve heart function performance,and have high safety and practicality in treatment.